Free Cash Flow CAGR:22.13%(TTM)
Free cash flow CAGR uses precomputed cash-flow statement history.
Over longer horizons, Free Cash Flow CAGR averages 5.02% over 3 years and 3.72% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Free cash flow CAGR measures how the company's cash generation has grown. FCF represents the cash available for dividends, buybacks, debt reduction, or reinvestment.
TECH Free Cash Flow CAGR Chart
Bio-Techne Corporation (TECH)
TECH Quarterly Free Cash Flow Growth (YoY)
Free Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
TECH Free Cash Flow CAGR History
| Year | Start FCF | End FCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $236.10M | $256.55M | +$20.45M | +8.66% | +8.66% |
| 2024 | $216.15M | $236.10M | +$19.95M | +9.23% | +9.23% |
| 2023 | $280.36M | $216.15M | $-64.22M | -22.90% | -22.90% |
| 2022 | $307.86M | $280.36M | $-27.50M | -8.93% | -8.93% |
| 2021 | $153.47M | $307.86M | +$154.39M | +100.60% | +100.60% |
| 2020 | $156.21M | $153.47M | $-2.73M | -1.75% | -1.75% |
| 2019 | $149.43M | $156.21M | +$6.78M | +4.53% | +4.53% |
| 2018 | $128.27M | $149.43M | +$21.16M | +16.50% | +16.50% |
| 2017 | $126.97M | $128.27M | +$1.30M | +1.02% | +1.02% |
| 2016 | $119.45M | $126.97M | +$7.52M | +6.29% | +6.29% |
| 2015 | $122.94M | $119.45M | $-3.49M | -2.84% | -2.84% |
| 2014 | $101.11M | $122.94M | +$21.83M | +21.59% | +21.59% |
| 2013 | $120.73M | $101.11M | $-19.62M | -16.25% | -16.25% |
| 2012 | $123.56M | $120.73M | $-2.83M | -2.29% | -2.29% |
| 2011 | $106.62M | $123.56M | +$16.95M | +15.90% | +15.90% |
| 2010 | $104.77M | $106.62M | +$1.85M | +1.77% | +1.77% |
| 2009 | $98.95M | $104.77M | +$5.81M | +5.87% | +5.87% |
| 2008 | $82.43M | $98.95M | +$16.52M | +20.05% | +20.05% |
| 2007 | $80.99M | $82.43M | +$1.44M | +1.78% | +1.78% |
| 2006 | $63.02M | $80.99M | +$17.96M | +28.50% | +28.50% |
| 2005 | $61.84M | $63.02M | +$1.18M | +1.91% | +1.91% |
| 2004 | $38.90M | $61.84M | +$22.95M | +59.00% | +59.00% |
| 2003 | $5.39M | $38.90M | +$33.50M | +621.49% | +621.49% |
| 2002 | $39.56M | $5.39M | $-34.17M | -86.37% | -86.37% |
| 2001 | $8.37M | $39.56M | +$31.19M | +372.51% | +372.51% |
| 2000 | $-2.20M | $8.37M | +$10.57M | N/A | N/A |
| 1999 | $17.30M | $-2.20M | $-19.50M | -112.72% | N/A |
| 1998 | $8.30M | $17.30M | +$9.00M | +108.43% | +108.43% |
| 1997 | $3.40M | $8.30M | +$4.90M | +144.12% | +144.12% |
Quarterly Free Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q3 2026 | $77.58M | +1.4% | +150.3% |
| Q2 2025 | $76.49M | +244.2% | -1.3% |
| Q1 2025 | $22.22M | -76.2% | -59.4% |
| Q4 2025 | $93.31M | +201.0% | +62.2% |
| Q3 2025 | $31.00M | -60.0% | -52.0% |
| Q2 2024 | $77.53M | +41.7% | +13.6% |
| Q1 2024 | $54.72M | -4.9% | +19.5% |
| Q4 2024 | $57.52M | -10.9% | -20.7% |
| Q3 2024 | $64.55M | -5.4% | +66.4% |
| Q2 2023 | $68.25M | +49.1% | +17.1% |
| Q1 2023 | $45.79M | -36.9% | -1.6% |
| Q4 2023 | $72.56M | +87.1% | -18.6% |
| Q3 2023 | $38.79M | -33.4% | -33.2% |
| Q2 2022 | $58.27M | +25.3% | -35.8% |
| Q1 2022 | $46.52M | -47.8% | +9.8% |
| Q4 2022 | $89.15M | +53.6% | -19.5% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman